Dr. Laura Fuhr

Rüdesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, Teutonico D, Schneider ARP, Solodenko J, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. A comprehensive CYP2D6 drug-drug-gene interaction network for application in precision dosing and drug development. Clinical Pharmacol. Ther. 2025. doi:10.1002/cpt.3604

Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, Schwab M, Lehr T. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13146

Loer HLH, Kovar C, Rüdesheim S, Marok FZ, Fuhr LM, Selzer D, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024;00:1-15.

Fuhr LM, Marok FZ, Fuhr U, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions. Clin Pharmacol Ther. 2023;114(2):470-482.

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug–drug interaction perpetrators. Pharmaceutics. 2023;15(2):679.

Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug-drug interaction modeling. Pharmaceutics 2022;14(7):1474.

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin on Drug Metab Toxicol 2021;17(11):1293-1310.

Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics 2021;13(3):331.

Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics 2021;13(2):270.

Fuhr LM, Hanke N, Meibohm B, Lehr T. Effective removal of dabigatran by idarucizumab or hemodialysis: a physiologically based pharmacokinetic modeling analysis. Clin Pharmacokinet 2020;59(6):809-825.